Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Products & Services, Business & People, Manufacturers & Providers

TITLE:

NICE: New technology appraisal on different treatments for people with severe rheumatoid arthritis

BRIEF:

The National Institute for Health and Care Excellence (NICE) recently published its final conclusions regarding adalimumab (Humira, Abbot), etanercept (Enbrel, Pfizer), infliximab (Remicade, Janssen; Remsima and Inflectra, Hospira), certolizumab pegol (Cimzia, UCB), golimumab (Simponi, Janssen), tocilizumab (RoActemra, Roche) and abatacept (Orencia, Bristol-Myers Squibb). 

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company